COMMUNIQUÉS West-GlobeNewswire

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
14/05/2025
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late [...]
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
14/05/2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the [...]
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
14/05/2025
MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine
14/05/2025
Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection and will be [...]
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
14/05/2025
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and [...]
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th
14/05/2025
MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance [...]
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
14/05/2025
- Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping cell-level [...]
Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
14/05/2025
Expanded life science and industrial portfolio with six additional life science products in development Advances toward commercialization of functional recombinant solutions for cell culture media, nucleic and [...]
Korro to Participate in Upcoming Investor Conferences
14/05/2025
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital [...]
SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates
14/05/2025
QUELIMMUNE adoption drives four-fold increase in sequential quarter net revenue NEUTRALIZE AKI trial exceeds 50% enrollment, triggers start of Interim Analysis Webcast Today at 4:30 pm Eastern Time DENVER, May 14, 2025 [...]
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results
14/05/2025
SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Codexis Reports First Quarter 2025 Financial Results
14/05/2025
Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual [...]
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May [...]
STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
14/05/2025
HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
14/05/2025
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, [...]
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in [...]
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
14/05/2025
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for [...]

Pages